Sutro Biopharma Inc.

Plus: Jane Chung named CEO of Sutro after strategic review, and Richard Law becomes CBO at Haya

Plus: Lange becomes CBO of Avidity and updates from CABS, BIO, Zevra and Achieve

Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships

Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira

Plus more antibody-drug conjugate deals: Ipsen-Sutro, Merck KGaA-Caris

Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM

Immunostimulatory antibody-drug conjugates move from concept to clinical product

Plus: Sutro promotes Chung to president and COO, and updates from Madrigal, MediWound, Diakonos and Acadia

Plus: Vertex’s diabetes cell therapy leads to insulin independence; Agios heads to Phase III in sickle cell; and updates from Biomea, Shionogi, Sagimet and more

Ted Love, BIO’s new chairman, to focus on Inflation Reduction Act, public perceptions